What we know about the Novavax vaccine: Yahoo News reveals

[ad_1]

US regulators have granted emergency use authorization for a new COVID-19 vaccine developed by Novavax. Dr. Monica Gandhi, an infectious disease specialist and professor of medicine at the University of California, San Francisco, explains what sets this new vaccine apart from Pfizer-BioNTech and modern shots and how it could compete with future variants .

video transcript

[MUSIC PLAYING]

, The original trial showed 90% effectiveness and that trial had a very high alpha. So 90.4% effectiveness to be exact. And in fact highly protective, even more so, up to 99% against serious illness.

[MUSIC PLAYING]

We don’t have Omicron specific data for Novavax, but we expect it to at least work as well as mRNA vaccines to protect against severe disease because it actually contains the same part of the virus, which is the spike protein. Is. Then there was another study at JAMA that was not a trial, but during the delta wave in India, they saw how Novavax was working because there are so many vaccines in India. So they looked at how Novavax was working during the Delta wave, and how it still provided protection for those health care workers who were exposed to Delta. So that was also very high, about 90%. So it’s not a test, but it gives you a good sense that it works well against the delta.

[MUSIC PLAYING]

Novavax differs from mRNA vaccines in that it uses this tried-and-true technique of delivering the actual spike protein, plus what we call “adjuvants,” an adjuvant. And then you take it into your body and then you increase the immune response against the spike protein, that whole spike protein. Whereas remember that the mRNA technology was showing you the genetic material for the host for the spike protein, and then you made the spike protein. So one more step and then you increase the immune response. So this is the actual protein. And it’s very traditional, there’s no live virus in it.

None of these vaccines for COVID are being dreamed up, there is no live virus in them. There are some people who don’t want to have mRNA and DNA vaccines for various reasons, and this gives us this additional vaccine, actually a much wider vaccine arsenal than we have in the rest of the world. And we want it for our vaccine-hesitant population who are waiting for a non-mRNA vaccine.

[MUSIC PLAYING]

One thing we’ve noticed is that when you mix vaccines, they work better than when you use the same vaccine as a booster. And that’s just because even though they’re all incorporating the spike protein, they fold differently and it could be that you just get a broad antigenic response called this. So it can be a good booster for people who have mRNA vaccine and booster.

[MUSIC PLAYING]

I think the more tools we have against COVID-19, the more we can stay out of the emergency phase and just continue to progress in our ways as we have to live with COVID. It’s not going to go away. So the more tools we have, the better.

[MUSIC PLAYING]

[ad_2]

Leave a Reply